Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to: "The endonuclease MCPIP1 protects against liver cancer development in a sex-dependent manner by modulating β-catenin and CREB1" [JHEP Reports 8 (2026) 101755].

JHEP reports : innovation in hepatology·2026
Same author

Trametinib Therapy for Hypertrophic Cardiomyopathy and Pulmonary Hypertension in a Child With RAF1-Related Noonan Syndrome (p.Ser257Leu): A Case Report.

Clinical case reports·2026
Same author

Extending structural surfaceomics to identify aberrant conformations of tumor surface proteins as potential immunotherapy targets.

bioRxiv : the preprint server for biology·2026
Same author

Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.

Blood·2026
Same author

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Blood·2026
Same author

A multi-subunit autophagic capture complex facilitates degradation of ER-stalled MHC class I in pancreatic cancer.

Molecular cell·2026

Related Experiment Video

Updated: Jul 1, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

896

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.

Corynn Kasap1,2, Adila Izgutdina2, Bonell Patiño-Escobar2

  • 1Dept. of Medicine, Division of Hematology/Oncology, University of California, San Francisco, CA.

Biorxiv : the Preprint Server for Biology
|March 11, 2024
PubMed
Summary
This summary is machine-generated.

Researchers identified CD70 as a promising target for high-risk multiple myeloma. A novel CD27-based CAR-T therapy targeting CD70 showed superior expansion and efficacy, offering a new treatment avenue.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

507
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

Related Experiment Videos

Last Updated: Jul 1, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

896
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

507
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Multiple myeloma patients with high-risk cytogenetics have poor outcomes despite BCMA-targeting CAR-T therapy.
  • There is an urgent need for novel therapeutic strategies to overcome resistance and relapse in these patients.

Purpose of the Study:

  • To identify novel cell surface antigens upregulated in high-risk multiple myeloma.
  • To develop and evaluate an optimized Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting a newly identified antigen.

Main Methods:

  • Structure-guided design of a CD27-based anti-CD70 CAR-T construct.
  • In vivo expansion studies comparing CD27-based CAR-T with scFv-based CARs.
  • Epigenetic analysis using machine learning to identify drivers of CD70 expression.
  • Development of dual-targeting CAR-Ts (CD70/BCMA).

Main Results:

  • CD70 was identified as a specifically upregulated antigen in high-risk myeloma tumors.
  • The CD27-based anti-CD70 CAR-T demonstrated >80-fold improved in vivo expansion compared to scFv-based CARs.
  • Machine learning predicted key transcription factors and networks driving CD70 upregulation.
  • Dual-targeting CAR-Ts showed potential to overcome antigen escape.

Conclusions:

  • CD70 is a promising therapeutic target for high-risk multiple myeloma.
  • Optimized CD27-based CAR-T designs offer enhanced efficacy and expansion.
  • Targeting CD70 represents a viable strategy to improve outcomes and overcome resistance in multiple myeloma, with potential for clinical translation.